Search

Displaying results 1991 - 2000 of 10000 in total
  1. Drug

    Sodium oxybate

    go.drugbank.com/drugs/DB09072
    ApprovedInvestigational

    [A251430] Due to its physiological effects, sodium oxybate is associated with a risk for substance misuse and abuse. … in May 2023.

  2. Drug

    Covax-19™

    go.drugbank.com/drugs/DB15846
    Investigational

    It uses an insect-cell-produced recombinant SARS-CoV-2 spike protein and Vaxine’s adjuvant, Advax-SM. … As of June 2020, the vaccine is in Phase 1 trials to evaluate safety and immune responses (NCT04428073).

  3. Drug

    Dextroamphetamine

    go.drugbank.com/drugs/DB01576
    ApprovedIllicitInvestigational

    Dextroamphetamine was approved by the FDA in 2001 for the treatment of attention deficit hyperactivity disorder.[L6010,L52145]

    Mixtures: Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate ER, Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate ERSynonyms: d-amphetamine
  4. Drug

    Enalaprilat

    go.drugbank.com/drugs/DB09477
    ApprovedInvestigational

    Used in the treatment of hypertension, enalapril is an ACE inhibitor that prevents Angiotensin Converting Enzyme (ACE) from transforming angiotensin I into angiotensin II. … Removal of the problematic thiol group from captopril resulted in enalaprilat, which was then modified further with an ester to create the orally available pro-drug enalapril.

    Categories: Agents Acting on the Renin-Angiotensin System
  5. Drug

    Iron Dextran

    go.drugbank.com/drugs/DB00893
    ApprovedInvestigationalVet approved

    Iron Dextran is used for the treatment of patients with documented iron deficiency in which oral administration is unsatisfactory or impossible.

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    Iopromide

    go.drugbank.com/drugs/DB09156
    Approved

    [A260751] Approved by the FDA in 1995 and Health Canada in 1994 under the brand name ULTRAVIST, iopromide is used in radiological diagnosis, including, but not limited to, intra-arterial digital subtraction … It functions as a contrast agent by opacifying blood vessels in the flow path of the contrast agent, permitting radiographic visualization of the internal structures until significant hemodilution occurs

    Categories: Compounds used in a research, industrial, or household settingSynonyms: N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-[(methoxyacetyl)amino]-N-methylisophthalamide
  7. Drug

    Insulin aspart

    go.drugbank.com/drugs/DB01306
    ApprovedInvestigational

    Due to its duration of action of around 5 hours, NovoRapid is considered "bolus insulin" as it provides high levels of insulin in a short period of time to mimic the release of endogenous insulin from … Insulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able

    Mixtures: NOVOMIX 30 FLEXPEN INJECTION 100 u/ml, NOVOMIX 30 FLEXPEN INJECTION 100 u/mlCategories: Drugs Used in Diabetes
  8. Drug

    Methylchloroisothiazolinone

    go.drugbank.com/drugs/DB14197
    Approved

    Methylchloroisothiazolinone (MCI) is an isothiazolinone commonly used as a preservative with antibacterial and antifungal properties. … It is also a known dermatological sensitizer and allergen; some of its side effects include flaky or scaly skin, breakouts, redness or itchiness, and moderate to severe swelling in the eye area.

    Categories: Compounds used in a research, industrial, or household settingSynonyms: 5-Chloro-N-methylisothiazolin-3-one
  9. Drug

    Olipudase alfa

    go.drugbank.com/drugs/DB12835
    ApprovedInvestigational

    [A251590] Olipudase alfa gained its first global approval in Japan on March 28, 2022. … [A251590] It was later approved by the European Commission on June 28, 2022 [L42740] and by the FDA on August 31, 2022.[L43145]

  10. Drug

    Respiratory syncytial virus vaccine, adjuvanted

    go.drugbank.com/drugs/DB17762
    ApprovedInvestigational

    [L46352] It was also later approved by Health Canada on August 4, 2023,[L47666] and the EMA in March 2025.[L52380] … [L46347] On May 3, 2023, it was approved by the FDA for immunization against lower respiratory tract disease (LRTD) as the first respiratory syncytial virus (RSV) vaccine approved in the United States